Coronary vasospasm and cardiovascular outcomes in patients with isolated myocardial bridging: A retrospective study
, 2, 23, 23, 23, 23, 23, 23, 23
Abstract
Background: Mounting evidence suggests an associated between myocardial bridging (MB) and coronary vasospasm (CVS); however, no consensus has been established on whether CVS worsens clinical outcomes in patients with MB. Therefore, this retrospective study aimed to compare the long-term clinical outcomes in patients with MB based on CVS presence.
Methods: This retrospective study enrolled 254 consecutive patients with MB undergoing provocative testing for coronary reactivity between January 1, 2009 and December 30, 2015, and stratified them into 2 groups: (a) group A (with CVS, n = 168); and (b) group B (without CVS, n = 86). The primary endpoints were major adverse cardiovascular events (MACEs), a composite of cardiac death, cardiac arrest, non-fatal myocardial infarction, ischemia-driven revascularization, ischemia-driven coronary angiography, and ischemia-related hospitalization. Diverse Cox models were used to determine whether CVS independently influenced MACE.
Results: The mean age of study participants was 50.8 years, and 60.2% of them were male. The median follow-up period was 8.15 years. The rate of MACE was 35.1% and 26.7% in groups A and B, respectively. Group A had a significantly higher risk of MACE than group B (the reference group) in model 3 (hazard ratio [HR]:1.92; 95% confidence interval [CI]:1.12–3.29) and model 4 (adjusted HR: 1.94; 95% CI: 1.04–3.59).
Conclusions: The presence of CVS adversely affects clinical outcomes in patients with MB. Further prospective clinical studies are required to confirm this association.
Keywords: comparative studycoronary vasospasmmyocardial bridgingoutcome assessment
References
- Sternheim D, Power DA, Samtani R, et al. Myocardial Bridging: Diagnosis, Functional Assessment, and Management: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021; 78(22): 2196–2212.
- Montone RA, Gurgoglione FL, Del Buono MG, et al. Interplay Between Myocardial Bridging and Coronary Spasm in Patients With Myocardial Ischemia and Non-Obstructive Coronary Arteries: Pathogenic and Prognostic Implications. J Am Heart Assoc. 2021; 10(14): e020535.
- Hostiuc S, Negoi I, Rusu MC, et al. Myocardial Bridging: A Meta-Analysis of Prevalence. J Forensic Sci. 2018; 63(4): 1176–1185.
- Teragawa H, Oshita C, Ueda T. The Myocardial Bridge: Potential Influences on the Coronary Artery Vasculature. Clin Med Insights Cardiol. 2019; 13: 1179546819846493.
- Kim SS, Jeong MHo, Kim HK, et al. Long-term clinical course of patients with isolated myocardial bridge. Circ J. 2010; 74(3): 538–543.
- Oh S, Hyun DY, Cho SG, et al. Case report: A fatal case of myocardial infarction due to myocardial bridge and concomitant vasospasm: the role of stress gated SPECT. Front Cardiovasc Med. 2023; 10: 1188095.
- Choi BG, Park SH, Rha SW, et al. Five-year clinical outcomes in patients with significant coronary artery spasm: A propensity score-matched analysis. Int J Cardiol. 2015; 184: 533–539.
- Kim JW, Park CG, Suh SY, et al. Comparison of frequency of coronary spasm in Korean patients with versus without myocardial bridging. Am J Cardiol. 2007; 100(7): 1083–1086.
- Nam P, Choi BG, Choi SeY, et al. The impact of myocardial bridge on coronary artery spasm and long-term clinical outcomes in patients without significant atherosclerotic stenosis. Atherosclerosis. 2018; 270: 8–12.
- Park T, Park JiY, Rha SW, et al. Impact of Diltiazem Alone versus Diltiazem with Nitrate on Five-Year Clinical Outcomes in Patients with Significant Coronary Artery Spasm. Yonsei Med J. 2017; 58(1): 90–98.
- Kim PJ, Hur G, Kim SuY, et al. Frequency of myocardial bridges and dynamic compression of epicardial coronary arteries: a comparison between computed tomography and invasive coronary angiography. Circulation. 2009; 119(10): 1408–1416.
- Corban MT, Hung OY, Eshtehardi P, et al. Myocardial bridging: contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies. J Am Coll Cardiol. 2014; 63(22): 2346–2355.
- Ge J, Jeremias A, Rupp A, et al. New signs characteristic of myocardial bridging demonstrated by intracoronary ultrasound and Doppler. Eur Heart J. 1999; 20(23): 1707–1716.
- Ishii T, Asuwa N, Masuda S, et al. Atherosclerosis suppression in the left anterior descending coronary artery by the presence of a myocardial bridge: an ultrastructural study. Mod Pathol. 1991; 4(4): 424–431.
- Ishikawa Y, Akasaka Y, Suzuki K, et al. Anatomic properties of myocardial bridge predisposing to myocardial infarction. Circulation. 2009; 120(5): 376–383.
- Möhlenkamp S, Hort W, Ge J, et al. Update on myocardial bridging. Circulation. 2002; 106(20): 2616–2622.
- Maseri A, Beltrame JF, Shimokawa H. Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets. Circ J. 2009; 73(3): 394–403.
- Teragawa H, Fukuda Y, Matsuda K, et al. Myocardial bridging increases the risk of coronary spasm. Clin Cardiol. 2003; 26(8): 377–383.
- Shiode N, Kato M, Teragawa H, et al. Vasomotility and nitric oxide bioactivity of the bridging segments of the left anterior descending coronary artery. Am J Cardiol. 1998; 81(3): 341–343.
- Herrmann J, Higano ST, Lenon RJ, et al. Myocardial bridging is associated with alteration in coronary vasoreactivity. Eur Heart J. 2004; 25(23): 2134–2142.
- Sara JDS, Corban MT, Prasad M, et al. Prevalence of myocardial bridging associated with coronary endothelial dysfunction in patients with chest pain and non-obstructive coronary artery disease. EuroIntervention. 2020; 15(14): 1262–1268.
- Kugiyama K, Murohara T, Yasue H, et al. Increased constrictor response to acetylcholine of the isolated coronary arteries from patients with variant angina. Int J Cardiol. 1995; 52(3): 223–233.
- Kugiyama K, Ohgushi M, Motoyama T, et al. Nitric oxide-mediated flow-dependent dilation is impaired in coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol. 1997; 30(4): 920–926.
- Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation. 1996; 94(3): 266–271.
- Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation. 1993; 87(1): 76–79.
- Park JiY, Rha SW, Li YJ, et al. Impact of hypertension on coronary artery spasm as assessed with intracoronary acetylcholine provocation test. J Hum Hypertens. 2010; 24(2): 77–85.
- Kook H, Hong SJ, Yang KS, et al. Comparison of nebivolol versus diltiazem in improving coronary artery spasm and quality of life in patients with hypertension and vasospastic angina: A prospective, randomized, double-blind pilot study. PLoS One. 2020; 15(9): e0239039.
- Takahashi J, Nihei T, Takagi Y, et al. Japanese Coronary Spasm Association. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association. Eur Heart J. 2015; 36(4): 228–237.
- Kim HJ, Jo SH, Lee MH, et al. Nitrates vs. Other Types of Vasodilators and Clinical Outcomes in Patients with Vasospastic Angina: A Propensity Score-Matched Analysis. J Clin Med. 2022; 11(12).
- Kim JiB, Choi BG, Rha SW. Prognostic impact of nitrate therapy in patients with myocardial bridge and coexisting coronary artery spasm. Heart Vessels. 2023; 38(3): 291–299.
- Hwang JHo, Ko SM, Roh HG, et al. Myocardial bridging of the left anterior descending coronary artery: depiction rate and morphologic features by dual-source CT coronary angiography. Korean J Radiol. 2010; 11(5): 514–521.
- Aleksandric SB, Djordjevic-Dikic AD, Dobric MR, et al. Functional Assessment of Myocardial Bridging With Conventional and Diastolic Fractional Flow Reserve: Vasodilator Versus Inotropic Provocation. J Am Heart Assoc. 2021; 10(13): e020597.
- Ong P, Athanasiadis A, Borgulya G, et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. 2008; 52(7): 523–527.
